Home

Biotech

Broadband

B2B Internet

Europe 2001

Internet

Internet 
Architecture

Internet 
Infrastructure

Market 2000+

Oil Services

Pharmaceutical

Regional Bank

Retail

Semiconductor

Software

Telecom

Utilities

Wireless
Nektar Therapeutics (NASDAQ GS:NKTR)7/28/2010
most recent headlinesmore headlines:       
WEDNESDAY, JULY 28, 2010
4:15 PMNektar Therapeutics Reports Second Quarter 2010 Financial Results - PR Newswire
WEDNESDAY, JULY 21, 2010
9:00 AMNektar to Announce Financial Results for the Second Quarter of 2010 On Wednesday, July 28, 2010, After Close of U.S.-Based Financial Markets - PR Newswire
MONDAY, JULY 19, 2010
8:00 AMTARIS Appoints Sarma Duddu as President and CEO - BusinessWire
TUESDAY, JULY 06, 2010
9:00 AMNKTR-102 Demonstrates Superior Activity to Irinotecan in Nonclinical Studies Presented at ESMO 12th World Congress on Gastrointestinal Cancer - PR Newswire
THURSDAY, JUNE 24, 2010
8:00 AMNektar Announces Dosing of First Patients in Phase 1 Clinical Study of NKTR-102 in Combination With 5-Fluorouracil/Leucovorin - PR Newswire
WEDNESDAY, JUNE 09, 2010
9:30 AMNektar Therapeutics Announces Positive Initial Results from Phase 2 Study of NKTR-102 in Metastatic Breast Cancer - PR Newswire
SUNDAY, JUNE 06, 2010
12:30 PMNKTR-102 Has High Response Rate and Sustained Clinical Benefit in 48 Percent of Women with Platinum-Resistant/Refractory Ovarian Cancer - PR Newswire
THURSDAY, JUNE 03, 2010
8:00 AMNektar Therapeutics' President and CEO Howard W. Robin to Present at the Jefferies 2010 Global Life Sciences Healthcare Conference in New York - PR Newswire
THURSDAY, MAY 20, 2010
7:16 PMNKTR-102 Phase 2 Clinical Data Accepted for Oral Presentation at 2010 ASCO Annual Meeting - PR Newswire
WEDNESDAY, MAY 05, 2010
4:15 PMNektar Therapeutics Reports First Quarter 2010 Financial Results - PR Newswire


Quotes delayed at least 15 minutes. Market data provided by Interactive Data.
Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions.

HOLDRS Defined |  HOLDRS Outstanding  |  FAQ  |  Proxies by email  |  Investment Strategies
Spin-Offs & Changes  |  Current Trading  |  Download a Prospectus  |  Site Map

Merrill Lynch, Pierce, Fenner & Smith Incorporated is a registered broker-dealer and a wholly-owned subsidiary of Bank of America Corporation.
Securities Products: Are Not FDIC Insured • Are Not Bank Guaranteed • May Lose Value.

The information in this Internet site is directed at, and is intended for distribution to, and for use by, persons in the U.S. only, and is not intended for distribution to or use by any person in any other jurisdiction. Merrill Lynch does not warrant the accuracy or completeness of any price, tax, cost basis, or other information on this site, or any investment, tax or other benefits associated with HOLDRS.

The information on HOLDRSSM contained in this Internet site is solely for informational purposes and does not constitute either an offer to sell or the solicitation of an offer to buy HOLDRS. This information on HOLDRS is not, and is not intended to be, a complete discussion of all material information you should know about HOLDRS. If you are considering whether to purchase a HOLDRS security, you should carefully read the relevant prospectus prior to making a purchase. You should not rely on the information contained in this Internet site. Please view Terms of Use and Legal Notices for additional important legal information and the terms and conditions governing your use of this site.

U.S. Patent Pending.
HOLDRS and HOLding Company Depositary ReceiptS are service marks of Merrill Lynch & Co., Inc.

© Copyright 2000, Merrill Lynch, Pierce, Fenner & Smith Incorporated. Member, Securities Investor Protection Corporation (SIPC). All rights reserved.